Intera Atlas
Run match
Sites / Tandem Clinical Research
Is this you?

Request access for Tandem Clinical Research with your @tandemclinicalresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Tandem Clinical Research

Unclaimed profile

Site Network · Marrero, LA (primary: 1111 Medical Center Blvd, Suite N308) · ~7 sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 8Lift (cardio sample) 0.06Recruit soph 0.71
Quality Scorecard (1–100)
Overall63Recruit65Ops60Sponsor66Ther60

Performance (observed)

Historical trials
162
Completed
73
Terminated/Withdrawn
25
Completion rate
74%
Active now
60
Phase 2
79
Phase 3
69
Realized enrollment
111,785
First study year
2017
Years active
9
Match confidence
high
Enrollment velocity (inf)
12,421

Therapeutic

Areas
Gastroenterology, CNS/neurology, pain, psychiatry, endocrinology, vaccines, women's health, dermatology, pediatrics, sleep disorders, ENT
Specialties
Vaccines, Neurology, GI, Pain, ENT, CNS, Pediatrics, Psychiatry, Endocrinology, Sleep, Dermatology, Women's Health
Breadth (conditions)
142
Languages
English + Spanish (detected)
States
LA, NY, NJ, FL

Recruitment (web observed)

Meta Pixel
Yes
Facebook Ads
Yes
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Multi-therapeutic trial recruitment presence
Capability notes
Strong; 400+ trials conducted; 90%+ enrollment success rate; rapid recruitment capability

Relationships

Sponsors
Janssen Research & Development, LLC; Eli Lilly and Company; Regeneron Pharmaceuticals; Phathom Pharmaceuticals, Inc.; Pfizer; Hoffmann-La Roche
CROs
PPD Development, LP; Teva Branded Pharmaceutical Products R&D LLC; Worldwide Clinical Trials
Partnerships
Prolerity Clinical Research (AHP majority investment, March 2024)
Owner / parent
Prolerity Clinical Research (AHP investment, Feb 2024); founders: Orlan Romm, Dr. Adil Fatakia, John Neill
Funding
AHP (Allied Healthcare Partners) - majority investment (March 2024)
Acquisitions
Majority acquired by Prolerity/AHP (March 2024)
Expansion
Y (400+ trials completed, network expansion via Prolerity)

Capacity & people

Investigators
—
Coordinators
—
CEO
Orlan Romm
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
info@tandemclinicalresearch.com; (504) 934-8424

Tech & DCT

Builds tech
Vendors (Prolerity partnership)
DCT / decentralized
Y (11 sites across LA, FL, NJ, NY)
Tech stack
Prolerity clinical research platform; partnership with ClinCloud
Recruiting visible
Y

Notes

Multi-state site network (7 sites across LA, FL, NY, NJ); strong enrollment performance (90%+ success); recruitment-constrained growth focus; 400+ trials demonstrates maturity. Excellent Intera fit—multiple recruiting studies visible, strong enrollment capability, growth-focused ownership (AHP investment), recruitment-centric model. Broad therapeutic mix supports volume. [Validated: 9 active recruiting cardiometabolic trials on ClinicalTrials.gov.]

Recommendation features (sample indication)

Ind fit 0.22Liftability 0.06Overall63

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.